Physician profile
Katy Dodt
NPI 1710609128
$4,902.80
in general payments reported to CMS, 2019-2025
34 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $1,072 · 2024: $1,887 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,723 · Education: $57.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,722.88 |
| Education | $57.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,246.90 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $663.72 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $409.11 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $360.00 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $306.49 | 2023-2025 | |
| Glaxosmithkline, LLC. | $239.85 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.28 | 2023-2025 | Caplyta |
| Amgen INC. | $219.08 | 2023-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $192.17 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $103.86 | 2022-2024 | Spravato |
| Horizon Therapeutics Plc | $101.17 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $86.51 | 2024-2025 | |
| Dexcom, INC. | $82.99 | 2024-2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $66.73 | 2022-2023 | Lybalvi |
| Tolmar, INC. | $63.92 | 2024-2025 | Jatenzo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.32 | 2022-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $56.60 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $50.31 | 2024 | Auvelity |
| Renalytix Ai, INC. | $41.09 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Currax Pharmaceuticals LLC | $37.74 | 2023 | Nexletol, Onzetra Xsail, Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.58 | 2024 | Jardiance |
| Inspire Medical Systems, INC. | $30.91 | 2024-2025 | Inspire |
| Almatica Pharma LLC | $29.21 | 2023 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $26.91 | 2023 | Jornay Pm |
| Eisai INC. | $23.85 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.35 | 2022 | |
| Halozyme INC | $19.61 | 2023 | |
| Lundbeck LLC | $18.35 | 2025 | Rexulti |
| Boston Scientific Corporation | $16.54 | 2024 | |
| Sumitomo Pharma America, INC. | $16.45 | 2025 | Gemtesa |
| Abbott Laboratories | $15.18 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $14.87 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $13.68 | 2025 | Gardasil 9, Capvaxive |
| Corium, LLC | $8.47 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Dodt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.